[1]
W. Xu, “CRISPR/Cas9-Mediated PD-1 Engineered T Cells: New Strategy to Block Tumor Immune Escape”, IJBLS, vol. 16, no. 1, pp. 252–255, Aug. 2026, doi: 10.54097/edfqwy74.